A month has passed by because the final earnings report for Ventas (VTR). Shares have added about 2.2% in that timeframe, outperforming the S&P 500.
Will the current constructive development proceed main as much as its subsequent earnings launch, or is Ventas due for a pullback? Earlier than we dive into how traders and analysts have reacted as of late, let’s take a fast take a look at the latest earnings report so as to get a greater deal with on the essential catalysts.
How Have Estimates Been Transferring Since Then?
It seems, estimates evaluation have trended downward throughout the previous month.
VGM Scores
Right now, Ventas has a subpar Development Rating of D, nevertheless its Momentum Rating is doing so much higher with an A. Nevertheless, the inventory was allotted a grade of D on the worth facet, placing it within the backside 40% for this funding technique.
General, the inventory has an mixture VGM Rating of D. When you aren’t centered on one technique, this rating is the one you ought to be fascinated with.
Outlook
Estimates have been broadly trending downward for the inventory, and the magnitude of those revisions has been web zero. Notably, Ventas has a Zacks Rank #3 (Maintain). We count on an in-line return from the inventory within the subsequent few months.
Efficiency of an Business Participant
Ventas is a part of the Zacks REIT and Fairness Belief – Different trade. Over the previous month, Healthpeak (DOC), a inventory from the identical trade, has gained 0.4%. The corporate reported its outcomes for the quarter ended December 2024 greater than a month in the past.
Healthpeak reported revenues of $697.99 million within the final reported quarter, representing a year-over-year change of +26.1%. EPS of $0.01 for a similar interval compares with $0.46 a yr in the past.
For the present quarter, Healthpeak is anticipated to put up earnings of $0.46 per share, indicating a change of +2.2% from the year-ago quarter. The Zacks Consensus Estimate has modified +0.3% over the past 30 days.
The general path and magnitude of estimate revisions translate right into a Zacks Rank #3 (Maintain) for Healthpeak. Additionally, the inventory has a VGM Rating of D.
Zacks’ Analysis Chief Names “Inventory Most Prone to Double”
Our group of specialists has simply launched the 5 shares with the best likelihood of gaining +100% or extra within the coming months. Of these 5, Director of Analysis Sheraz Mian highlights the one inventory set to climb highest.
This high choose is among the many most modern monetary companies. With a fast-growing buyer base (already 50+ million) and a various set of innovative options, this inventory is poised for large beneficial properties. In fact, all our elite picks aren’t winners however this one might far surpass earlier Zacks’ Shares Set to Double like Nano-X Imaging which shot up +129.6% in little greater than 9 months.
Free: See Our Top Stock And 4 Runners Up
Ventas, Inc. (VTR) : Free Stock Analysis Report
Healthpeak Properties, Inc. (DOC) : Free Stock Analysis Report
This article originally published on Zacks Investment Research (zacks.com).
The views and opinions expressed herein are the views and opinions of the writer and don’t essentially replicate these of Nasdaq, Inc.
